The COOH-terminal Src kinase Csk is a tumor antigen in human carcinoma.
The cytoplasmic tyrosine kinase cSrc is involved in the regulation of many important cellular functions including cell growth and transformation, and its activity is down-regulated by phosphorylation of the Tyr530 residue by the COOH-terminal Src tyrosine kinase, Csk. Because cSrc was previously found overexpressed, activated, and in some cases mutated in carcinoma, we investigated whether it could act as a tumor antigen. We show that whereas no autoantibodies were found against cSrc or its relative Fyn, up to 20% of patients with carcinoma had high-affinity autoantibodies against Csk. Immunity mainly resulted from a secondary response, as indicated by the presence of IgG1 in the sera. Antibodies were linked to the cancer because they were not detected in healthy subjects nor in patients with unrelated diseases, and their levels decreased in the sera of patients after surgical resection. Furthermore, they behaved as early markers of epithelial transformation because they were present in sera of patients with early-stage tumors and precancerous lesions such as colorectal polyps and in sera of patients that were scored negative for other cancer serological markers (CEA, CA15-3, CA19-9, p53 antibodies). Finally the presence of these antibodies was attributed, at least in part, to a substantial elevation of Csk protein levels in the corresponding tumors. However a strong increase in Src activity was also observed in these tissues, which suggested that Csk cannot regulate Src-like activity in carcinoma. Taken together, these data demonstrate that Csk acts as an autoantigen, and the detection of anti-Csk antibodies may have potential diagnostic usefulness in the early detection and postoperative follow-up of patients with carcinoma.
Centre National de la Recherche Scientifique, Unité Propre de Recherche, Montpellier, France. benistant@crbm.cnrs-mop.fr
C
C
Bénistant
J F
JF
Bourgaux
H
H
Chapuis
N
N
Mottet
S
S
Roche
J P
JP
Bali
D000230:Adenocarcinoma / Q000201:enzymology / Q000276:immunology*; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000951:Antigens, Neoplasm / Q000096:biosynthesis / Q000276:immunology* / Q000378:metabolism; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D016367:Baculoviridae / Q000235:genetics; D014408:Biomarkers, Tumor / Q000276:immunology*; D019556:COS Cells / Q000378:metabolism; D000081247:CSK Tyrosine-Protein Kinase; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000201:enzymology / Q000276:immunology*; D011505:Protein-Tyrosine Kinases / Q000096:biosynthesis / Q000276:immunology* / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000276:immunology; D051076:Proto-Oncogene Proteins c-fyn; D018411:Spodoptera / Q000821:virology; D018909:src Homology Domains / Q000276:immunology*; D019061:src-Family Kinases
D000951:Antigens, Neoplasm; D001323:Autoantibodies; D014408:Biomarkers, Tumor; D011518:Proto-Oncogene Proteins; D011505:Protein-Tyrosine Kinases; D000081247:CSK Tyrosine-Protein Kinase; C494957:FYN protein, human; D051076:Proto-Oncogene Proteins c-fyn; D019061:src-Family Kinases; C000631346:CSK protein, human